GlucoTrack, Inc.
Get $10 bonus on your first $100 deposit for IGAP
Get $10 bonus on your first $100 deposit for IGAP
GlucoTrack, Inc. (IGAP) Stock Competitors & Peer Comparison
See (IGAP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IGAP | $3.24 | +2.86% | 50.2M | -10.52 | -$0.31 | N/A |
| ISRG | $452.07 | -2.67% | 160.5B | 57.37 | $7.88 | N/A |
| BDX | $154.51 | -1.17% | 56B | 25.29 | $6.11 | +2.27% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.27% |
| ALC | $74.56 | -1.26% | 36.3B | 37.66 | $1.98 | +0.45% |
| MDLN | $44.28 | +0.64% | 35.9B | 30.97 | $1.43 | N/A |
| RMD | $224.09 | +0.56% | 32.7B | 22.14 | $10.12 | +1.04% |
| WST | $254.80 | +0.82% | 18.4B | 37.58 | $6.78 | +0.34% |
| HOLX | $75.65 | +0.07% | 16.9B | 31.39 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.27% |
Stock Comparison
IGAP vs ISRG Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ISRG has a market cap of 160.5B. Regarding current trading prices, IGAP is priced at $3.24, while ISRG trades at $452.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ISRG's P/E ratio is 57.37. In terms of profitability, IGAP's ROE is +0.00%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, IGAP is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ISRG's competition here
IGAP vs BDX Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDX has a market cap of 56B. Regarding current trading prices, IGAP is priced at $3.24, while BDX trades at $154.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDX's P/E ratio is 25.29. In terms of profitability, IGAP's ROE is +0.00%, compared to BDX's ROE of +0.07%. Regarding short-term risk, IGAP is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check BDX's competition here
IGAP vs BDXA Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, IGAP is priced at $3.24, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDXA's P/E ratio is 21.44. In terms of profitability, IGAP's ROE is +0.00%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, IGAP is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check BDXA's competition here
IGAP vs ALC Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ALC has a market cap of 36.3B. Regarding current trading prices, IGAP is priced at $3.24, while ALC trades at $74.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ALC's P/E ratio is 37.66. In terms of profitability, IGAP's ROE is +0.00%, compared to ALC's ROE of +0.04%. Regarding short-term risk, IGAP is less volatile compared to ALC. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ALC's competition here
IGAP vs MDLN Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MDLN has a market cap of 35.9B. Regarding current trading prices, IGAP is priced at $3.24, while MDLN trades at $44.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MDLN's P/E ratio is 30.97. In terms of profitability, IGAP's ROE is +0.00%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, IGAP is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check MDLN's competition here
IGAP vs RMD Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RMD has a market cap of 32.7B. Regarding current trading prices, IGAP is priced at $3.24, while RMD trades at $224.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RMD's P/E ratio is 22.14. In terms of profitability, IGAP's ROE is +0.00%, compared to RMD's ROE of +0.25%. Regarding short-term risk, IGAP is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check RMD's competition here
IGAP vs WST Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, WST has a market cap of 18.4B. Regarding current trading prices, IGAP is priced at $3.24, while WST trades at $254.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas WST's P/E ratio is 37.58. In terms of profitability, IGAP's ROE is +0.00%, compared to WST's ROE of +0.17%. Regarding short-term risk, IGAP is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check WST's competition here
IGAP vs HOLX Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HOLX has a market cap of 16.9B. Regarding current trading prices, IGAP is priced at $3.24, while HOLX trades at $75.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HOLX's P/E ratio is 31.39. In terms of profitability, IGAP's ROE is +0.00%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, IGAP is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check HOLX's competition here
IGAP vs BDXB Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, IGAP is priced at $3.24, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDXB's P/E ratio is 7.60. In terms of profitability, IGAP's ROE is +0.00%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, IGAP is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check BDXB's competition here
IGAP vs COO Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, IGAP is priced at $3.24, while COO trades at $70.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas COO's P/E ratio is 34.91. In terms of profitability, IGAP's ROE is +0.00%, compared to COO's ROE of +0.05%. Regarding short-term risk, IGAP is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check COO's competition here
IGAP vs MASI Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MASI has a market cap of 9.6B. Regarding current trading prices, IGAP is priced at $3.24, while MASI trades at $178.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MASI's P/E ratio is 46.63. In terms of profitability, IGAP's ROE is +0.00%, compared to MASI's ROE of -0.17%. Regarding short-term risk, IGAP is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check MASI's competition here
IGAP vs BAX Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BAX has a market cap of 8.6B. Regarding current trading prices, IGAP is priced at $3.24, while BAX trades at $16.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BAX's P/E ratio is -9.53. In terms of profitability, IGAP's ROE is +0.00%, compared to BAX's ROE of -0.14%. Regarding short-term risk, IGAP is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check BAX's competition here
IGAP vs ATR Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATR has a market cap of 8.1B. Regarding current trading prices, IGAP is priced at $3.24, while ATR trades at $126.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATR's P/E ratio is 21.39. In terms of profitability, IGAP's ROE is +0.00%, compared to ATR's ROE of +0.15%. Regarding short-term risk, IGAP is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ATR's competition here
IGAP vs RGEN Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RGEN has a market cap of 6.6B. Regarding current trading prices, IGAP is priced at $3.24, while RGEN trades at $117.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RGEN's P/E ratio is 136.95. In terms of profitability, IGAP's ROE is +0.00%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, IGAP is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check RGEN's competition here
IGAP vs BLCO Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, IGAP is priced at $3.24, while BLCO trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BLCO's P/E ratio is -16.17. In terms of profitability, IGAP's ROE is +0.00%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, IGAP is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check BLCO's competition here
IGAP vs AVTR Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AVTR has a market cap of 5.4B. Regarding current trading prices, IGAP is priced at $3.24, while AVTR trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AVTR's P/E ratio is -10.13. In terms of profitability, IGAP's ROE is +0.00%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, IGAP is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check AVTR's competition here
IGAP vs TFX Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, TFX has a market cap of 5.2B. Regarding current trading prices, IGAP is priced at $3.24, while TFX trades at $117.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas TFX's P/E ratio is 89.93. In terms of profitability, IGAP's ROE is +0.00%, compared to TFX's ROE of -0.24%. Regarding short-term risk, IGAP is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check TFX's competition here
IGAP vs MMSI Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MMSI has a market cap of 4B. Regarding current trading prices, IGAP is priced at $3.24, while MMSI trades at $67.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MMSI's P/E ratio is 31.78. In terms of profitability, IGAP's ROE is +0.00%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, IGAP is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check MMSI's competition here
IGAP vs STVN Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, IGAP is priced at $3.24, while STVN trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STVN's P/E ratio is 23.27. In terms of profitability, IGAP's ROE is +0.00%, compared to STVN's ROE of +0.10%. Regarding short-term risk, IGAP is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check STVN's competition here
IGAP vs ICUI Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ICUI has a market cap of 3B. Regarding current trading prices, IGAP is priced at $3.24, while ICUI trades at $123.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ICUI's P/E ratio is 6165.50. In terms of profitability, IGAP's ROE is +0.00%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, IGAP is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ICUI's competition here
IGAP vs HAE Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HAE has a market cap of 2.7B. Regarding current trading prices, IGAP is priced at $3.24, while HAE trades at $56.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HAE's P/E ratio is 15.66. In terms of profitability, IGAP's ROE is +0.00%, compared to HAE's ROE of +0.20%. Regarding short-term risk, IGAP is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check HAE's competition here
IGAP vs WRBY Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, WRBY has a market cap of 2.5B. Regarding current trading prices, IGAP is priced at $3.24, while WRBY trades at $20.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas WRBY's P/E ratio is 2029.00. In terms of profitability, IGAP's ROE is +0.00%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, IGAP is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check WRBY's competition here
IGAP vs LMAT Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LMAT has a market cap of 2.5B. Regarding current trading prices, IGAP is priced at $3.24, while LMAT trades at $108.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LMAT's P/E ratio is 43.05. In terms of profitability, IGAP's ROE is +0.00%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, IGAP is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check LMAT's competition here
IGAP vs XRAY Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, IGAP is priced at $3.24, while XRAY trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas XRAY's P/E ratio is -3.88. In terms of profitability, IGAP's ROE is +0.00%, compared to XRAY's ROE of -0.35%. Regarding short-term risk, IGAP is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check XRAY's competition here
IGAP vs PLSE Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, PLSE has a market cap of 1.6B. Regarding current trading prices, IGAP is priced at $3.24, while PLSE trades at $23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas PLSE's P/E ratio is -21.30. In terms of profitability, IGAP's ROE is +0.00%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, IGAP is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check PLSE's competition here
IGAP vs ATRC Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, IGAP is priced at $3.24, while ATRC trades at $29.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRC's P/E ratio is -121.12. In terms of profitability, IGAP's ROE is +0.00%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, IGAP is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ATRC's competition here
IGAP vs NVCR Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NVCR has a market cap of 1.2B. Regarding current trading prices, IGAP is priced at $3.24, while NVCR trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NVCR's P/E ratio is -8.65. In terms of profitability, IGAP's ROE is +0.00%, compared to NVCR's ROE of -0.39%. Regarding short-term risk, IGAP is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check NVCR's competition here
IGAP vs QDEL Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, QDEL has a market cap of 1.2B. Regarding current trading prices, IGAP is priced at $3.24, while QDEL trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas QDEL's P/E ratio is -1.03. In terms of profitability, IGAP's ROE is +0.00%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, IGAP is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check QDEL's competition here
IGAP vs KMTS Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, IGAP is priced at $3.24, while KMTS trades at $19.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas KMTS's P/E ratio is -3.63. In terms of profitability, IGAP's ROE is +0.00%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, IGAP is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check KMTS's competition here
IGAP vs NNNN Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NNNN has a market cap of 1.1B. Regarding current trading prices, IGAP is priced at $3.24, while NNNN trades at $25.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NNNN's P/E ratio is 430.83. In terms of profitability, IGAP's ROE is +0.00%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, IGAP is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check NNNN's competition here
IGAP vs AZTA Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AZTA has a market cap of 1B. Regarding current trading prices, IGAP is priced at $3.24, while AZTA trades at $22.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AZTA's P/E ratio is 39.02. In terms of profitability, IGAP's ROE is +0.00%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, IGAP is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check AZTA's competition here
IGAP vs STAA Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STAA has a market cap of 1B. Regarding current trading prices, IGAP is priced at $3.24, while STAA trades at $20.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STAA's P/E ratio is -12.48. In terms of profitability, IGAP's ROE is +0.00%, compared to STAA's ROE of -0.23%. Regarding short-term risk, IGAP is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check STAA's competition here
IGAP vs BLFS Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BLFS has a market cap of 942.3M. Regarding current trading prices, IGAP is priced at $3.24, while BLFS trades at $19.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BLFS's P/E ratio is -78.04. In terms of profitability, IGAP's ROE is +0.00%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, IGAP is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check BLFS's competition here
IGAP vs ATRI Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, IGAP is priced at $3.24, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRI's P/E ratio is 64.50. In terms of profitability, IGAP's ROE is +0.00%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, IGAP is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check ATRI's competition here
IGAP vs ANGO Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ANGO has a market cap of 425M. Regarding current trading prices, IGAP is priced at $3.24, while ANGO trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ANGO's P/E ratio is -13.57. In terms of profitability, IGAP's ROE is +0.00%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, IGAP is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ANGO's competition here
IGAP vs OSUR Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, OSUR has a market cap of 212.9M. Regarding current trading prices, IGAP is priced at $3.24, while OSUR trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas OSUR's P/E ratio is -3.28. In terms of profitability, IGAP's ROE is +0.00%, compared to OSUR's ROE of -0.19%. Regarding short-term risk, IGAP is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check OSUR's competition here
IGAP vs UTMD Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, UTMD has a market cap of 202.2M. Regarding current trading prices, IGAP is priced at $3.24, while UTMD trades at $63.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas UTMD's P/E ratio is 18.14. In terms of profitability, IGAP's ROE is +0.00%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, IGAP is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check UTMD's competition here
IGAP vs KRMD Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, KRMD has a market cap of 200.3M. Regarding current trading prices, IGAP is priced at $3.24, while KRMD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas KRMD's P/E ratio is -72.00. In terms of profitability, IGAP's ROE is +0.00%, compared to KRMD's ROE of -0.16%. Regarding short-term risk, IGAP is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check KRMD's competition here
IGAP vs INFU Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, INFU has a market cap of 188.9M. Regarding current trading prices, IGAP is priced at $3.24, while INFU trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas INFU's P/E ratio is 29.97. In terms of profitability, IGAP's ROE is +0.00%, compared to INFU's ROE of +0.12%. Regarding short-term risk, IGAP is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check INFU's competition here
IGAP vs STXS Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STXS has a market cap of 181.9M. Regarding current trading prices, IGAP is priced at $3.24, while STXS trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STXS's P/E ratio is -7.48. In terms of profitability, IGAP's ROE is +0.00%, compared to STXS's ROE of -1.92%. Regarding short-term risk, IGAP is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check STXS's competition here
IGAP vs PDEX Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, PDEX has a market cap of 168.5M. Regarding current trading prices, IGAP is priced at $3.24, while PDEX trades at $51.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas PDEX's P/E ratio is 15.15. In terms of profitability, IGAP's ROE is +0.00%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, IGAP is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check PDEX's competition here
IGAP vs SMTI Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, SMTI has a market cap of 158M. Regarding current trading prices, IGAP is priced at $3.24, while SMTI trades at $17.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas SMTI's P/E ratio is -344.80. In terms of profitability, IGAP's ROE is +0.00%, compared to SMTI's ROE of -1.79%. Regarding short-term risk, IGAP is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check SMTI's competition here
IGAP vs NYXH Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NYXH has a market cap of 132.9M. Regarding current trading prices, IGAP is priced at $3.24, while NYXH trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NYXH's P/E ratio is -1.30. In terms of profitability, IGAP's ROE is +0.00%, compared to NYXH's ROE of -1.35%. Regarding short-term risk, IGAP is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check NYXH's competition here
IGAP vs MBOT Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MBOT has a market cap of 109.4M. Regarding current trading prices, IGAP is priced at $3.24, while MBOT trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MBOT's P/E ratio is -8.28. In terms of profitability, IGAP's ROE is +0.00%, compared to MBOT's ROE of -0.24%. Regarding short-term risk, IGAP is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check MBOT's competition here
IGAP vs AKYA Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, IGAP is priced at $3.24, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AKYA's P/E ratio is -1.34. In terms of profitability, IGAP's ROE is +0.00%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, IGAP is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check AKYA's competition here
IGAP vs ZTEK Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ZTEK has a market cap of 56.6M. Regarding current trading prices, IGAP is priced at $3.24, while ZTEK trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ZTEK's P/E ratio is -8.77. In terms of profitability, IGAP's ROE is +0.00%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, IGAP is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ZTEK's competition here
IGAP vs OMIC Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, IGAP is priced at $3.24, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas OMIC's P/E ratio is -0.58. In terms of profitability, IGAP's ROE is +0.00%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, IGAP is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check OMIC's competition here
IGAP vs DXR Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, DXR has a market cap of 48.9M. Regarding current trading prices, IGAP is priced at $3.24, while DXR trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas DXR's P/E ratio is 5.91. In terms of profitability, IGAP's ROE is +0.00%, compared to DXR's ROE of +0.22%. Regarding short-term risk, IGAP is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check DXR's competition here
IGAP vs STSS Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STSS has a market cap of 43.8M. Regarding current trading prices, IGAP is priced at $3.24, while STSS trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STSS's P/E ratio is -0.14. In terms of profitability, IGAP's ROE is +0.00%, compared to STSS's ROE of -1.56%. Regarding short-term risk, IGAP is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check STSS's competition here
IGAP vs POCI Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, POCI has a market cap of 33M. Regarding current trading prices, IGAP is priced at $3.24, while POCI trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas POCI's P/E ratio is -4.59. In terms of profitability, IGAP's ROE is +0.00%, compared to POCI's ROE of -0.61%. Regarding short-term risk, IGAP is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check POCI's competition here
IGAP vs NEPH Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NEPH has a market cap of 30.5M. Regarding current trading prices, IGAP is priced at $3.24, while NEPH trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NEPH's P/E ratio is 26.09. In terms of profitability, IGAP's ROE is +0.00%, compared to NEPH's ROE of +0.12%. Regarding short-term risk, IGAP is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check NEPH's competition here
IGAP vs SDC Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, IGAP is priced at $3.24, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas SDC's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +0.00%, compared to SDC's ROE of -1.96%. Regarding short-term risk, IGAP is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check SDC's competition here
IGAP vs IVC Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, IGAP is priced at $3.24, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IVC's P/E ratio is -0.79. In terms of profitability, IGAP's ROE is +0.00%, compared to IVC's ROE of -0.46%. Regarding short-term risk, IGAP is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check IVC's competition here
IGAP vs HBIO Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HBIO has a market cap of 23.3M. Regarding current trading prices, IGAP is priced at $3.24, while HBIO trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HBIO's P/E ratio is -0.41. In terms of profitability, IGAP's ROE is +0.00%, compared to HBIO's ROE of -3.89%. Regarding short-term risk, IGAP is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check HBIO's competition here
IGAP vs EKSO Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, EKSO has a market cap of 22.8M. Regarding current trading prices, IGAP is priced at $3.24, while EKSO trades at $9.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas EKSO's P/E ratio is -1.91. In terms of profitability, IGAP's ROE is +0.00%, compared to EKSO's ROE of -1.11%. Regarding short-term risk, IGAP is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check EKSO's competition here
IGAP vs MLSS Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MLSS has a market cap of 22.3M. Regarding current trading prices, IGAP is priced at $3.24, while MLSS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MLSS's P/E ratio is -4.06. In terms of profitability, IGAP's ROE is +0.00%, compared to MLSS's ROE of -1.74%. Regarding short-term risk, IGAP is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check MLSS's competition here
IGAP vs RVP Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RVP has a market cap of 20.6M. Regarding current trading prices, IGAP is priced at $3.24, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RVP's P/E ratio is -1.60. In terms of profitability, IGAP's ROE is +0.00%, compared to RVP's ROE of -0.17%. Regarding short-term risk, IGAP is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check RVP's competition here
IGAP vs ZJYL Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ZJYL has a market cap of 14.5M. Regarding current trading prices, IGAP is priced at $3.24, while ZJYL trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ZJYL's P/E ratio is 185.00. In terms of profitability, IGAP's ROE is +0.00%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, IGAP is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check ZJYL's competition here
IGAP vs FEMY Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, FEMY has a market cap of 12.9M. Regarding current trading prices, IGAP is priced at $3.24, while FEMY trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas FEMY's P/E ratio is -0.93. In terms of profitability, IGAP's ROE is +0.00%, compared to FEMY's ROE of -5.35%. Regarding short-term risk, IGAP is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check FEMY's competition here
IGAP vs RGNT Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RGNT has a market cap of 12.2M. Regarding current trading prices, IGAP is priced at $3.24, while RGNT trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RGNT's P/E ratio is -0.13. In terms of profitability, IGAP's ROE is +0.00%, compared to RGNT's ROE of N/A. Regarding short-term risk, IGAP is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check RGNT's competition here
IGAP vs NXGL Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NXGL has a market cap of 6.3M. Regarding current trading prices, IGAP is priced at $3.24, while NXGL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NXGL's P/E ratio is -1.56. In terms of profitability, IGAP's ROE is +0.00%, compared to NXGL's ROE of -0.61%. Regarding short-term risk, IGAP is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check NXGL's competition here
IGAP vs NSTG Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, IGAP is priced at $3.24, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NSTG's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +0.00%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, IGAP is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check NSTG's competition here
IGAP vs LUCY Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LUCY has a market cap of 4.2M. Regarding current trading prices, IGAP is priced at $3.24, while LUCY trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LUCY's P/E ratio is -0.56. In terms of profitability, IGAP's ROE is +0.00%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, IGAP is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check LUCY's competition here
IGAP vs NXGLW Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NXGLW has a market cap of 3.1M. Regarding current trading prices, IGAP is priced at $3.24, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +0.00%, compared to NXGLW's ROE of -0.61%. Regarding short-term risk, IGAP is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check NXGLW's competition here
IGAP vs POAI Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, POAI has a market cap of 3M. Regarding current trading prices, IGAP is priced at $3.24, while POAI trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas POAI's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +0.00%, compared to POAI's ROE of +29.59%. Regarding short-term risk, IGAP is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check POAI's competition here
IGAP vs MHUA Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MHUA has a market cap of 2.6M. Regarding current trading prices, IGAP is priced at $3.24, while MHUA trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MHUA's P/E ratio is 0.27. In terms of profitability, IGAP's ROE is +0.00%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, IGAP is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check MHUA's competition here
IGAP vs GMVD Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, IGAP is priced at $3.24, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GMVD's P/E ratio is -0.01. In terms of profitability, IGAP's ROE is +0.00%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, IGAP is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check GMVD's competition here
IGAP vs GMVDW Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, IGAP is priced at $3.24, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GMVDW's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +0.00%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, IGAP is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check GMVDW's competition here
IGAP vs AVGR Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, IGAP is priced at $3.24, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AVGR's P/E ratio is -0.05. In terms of profitability, IGAP's ROE is +0.00%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, IGAP is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check AVGR's competition here
IGAP vs GCTK Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GCTK has a market cap of 488K. Regarding current trading prices, IGAP is priced at $3.24, while GCTK trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GCTK's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +0.00%, compared to GCTK's ROE of -3.93%. Regarding short-term risk, IGAP is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check GCTK's competition here
IGAP vs LUCYW Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, IGAP is priced at $3.24, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LUCYW's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +0.00%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, IGAP is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check LUCYW's competition here
IGAP vs WOK Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, WOK has a market cap of 6.6K. Regarding current trading prices, IGAP is priced at $3.24, while WOK trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas WOK's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +0.00%, compared to WOK's ROE of -0.07%. Regarding short-term risk, IGAP is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.Check WOK's competition here
IGAP vs HRC Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HRC has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HRC's P/E ratio is 41.92. In terms of profitability, IGAP's ROE is +0.00%, compared to HRC's ROE of +0.14%. Regarding short-term risk, IGAP is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check HRC's competition here
IGAP vs IIN Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IIN has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IIN's P/E ratio is 226.45. In terms of profitability, IGAP's ROE is +0.00%, compared to IIN's ROE of -0.00%. Regarding short-term risk, IGAP is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check IIN's competition here
IGAP vs ARTC Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ARTC has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ARTC's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +0.00%, compared to ARTC's ROE of N/A. Regarding short-term risk, IGAP is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check ARTC's competition here
IGAP vs IVTY Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IVTY's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +0.00%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, IGAP is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check IVTY's competition here
IGAP vs APR Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, APR has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas APR's P/E ratio is 22.59. In terms of profitability, IGAP's ROE is +0.00%, compared to APR's ROE of +9.81%. Regarding short-term risk, IGAP is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check APR's competition here
IGAP vs ATRS Comparison April 2026
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRS's P/E ratio is 14.95. In terms of profitability, IGAP's ROE is +0.00%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, IGAP is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.Check ATRS's competition here